Recruiting
Phase 1

Observational Study

Sponsor:

Zydus Therapeutics Inc.

Code:

NCT05045482

Conditions

Hepatic Impairment

Cirrhosis

Cholestatic Liver Disease

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

Saroglitazar Magnesium 1 mg

Saroglitazar Magnesium 2 mg

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-30. This information was provided to ClinicalTrials.gov by Zydus Therapeutics Inc. on 2025-08-15.